Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Prospective, Multi-center, Open-label Trial to Assess the Safety and Efficacy of Cellular Immunotherapy With MDR-103 for Induction of Mixed Chimerism and Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants

Trial Profile

A Phase 2 Prospective, Multi-center, Open-label Trial to Assess the Safety and Efficacy of Cellular Immunotherapy With MDR-103 for Induction of Mixed Chimerism and Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MDR 103 (Primary) ; Antithymocyte globulin
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Medeor Therapeutics
  • Most Recent Events

    • 11 Apr 2019 Planned initiation date changed from 1 Aug 2018 to 31 Aug 2019.
    • 11 Apr 2019 Status has been changed to not yet recruiting.
    • 02 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top